{"id":"cgb-500-ointment-with-1-tofacitinib","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL2103743","moleculeType":"Small molecule","molecularWeight":"504.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting JAK enzymes, tofacitinib reduces the production of pro-inflammatory cytokines, thereby decreasing inflammation and modulating the immune response. This mechanism of action is thought to contribute to its therapeutic effects in treating various inflammatory conditions.","oneSentence":"Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:50:23.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT06923228","phase":"PHASE2","title":"A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"CAGE Bio Inc.","startDate":"2025-04-21","conditions":"Atopic Dermatitis (AD)","enrollment":3},{"nctId":"NCT06810050","phase":"PHASE2","title":"Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis","status":"RECRUITING","sponsor":"CAGE Bio Inc.","startDate":"2024-12-18","conditions":"Atopic Dermatitis (AD)","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CGB-500 Ointment with 1% tofacitinib","genericName":"CGB-500 Ointment with 1% tofacitinib","companyName":"CAGE Bio Inc.","companyId":"cage-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation. Used for Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}